Athersys Inc. (NSDQ:ATHX) reported more positive results from an ongoing Phase 1 clinical trial of its adult stem cell therapy for the treatment of heart-attack patients.
The new data show that Athersys’ MultiStem treatment was well-tolerated at all dose levels and also suggest improvement in heart function in treated patients. The newly announced results are based on four months of data on patients who were treated with MultiStem after suffering acute myocardial infarctions, or heart attacks, according to the company.